Filing Details
- Accession Number:
- 0001209191-11-051774
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-10-14 16:39:37
- Reporting Period:
- 2011-10-12
- Filing Date:
- 2011-10-14
- Accepted Time:
- 2011-10-14 16:39:37
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1138400 | Biomimetic Therapeutics Inc. | BMTI | Surgical & Medical Instruments & Apparatus (3841) | 621786244 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1362155 | Martin Earl Douglas | Biomimetic Therapeutics, Inc. 389 Nichol Mill Lane Franklin TN 37067 | General Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2011-10-12 | 3,000 | $2.99 | 63,144 | No | 4 | S | Direct | |
Common Stock | Disposition | 2011-10-13 | 3,000 | $2.98 | 60,144 | No | 4 | S | Direct | |
Common Stock | Disposition | 2011-10-14 | 3,000 | $3.06 | 57,144 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- This transaction represents the sale of 3,000 shares of common stock beneficially owned by the Reporting Person, and was made pursuant to the Reporting Person's participation in a Sales Plan to sell shares of the Issuer's common stock in accordance with the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The Sales Plan was adopted in May 2011 and was designed to allow the Reporting Person to meet Federal income tax obligations due on October 15, 2011 resulting from alternative minimum tax liability based on the Reporting Person's exercise of Issuer's stock options in 2010.
- This price represents the weighted average sales price of multiple transactions on the reported date at prices that ranged between $2.99 and $2.9913. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.
- This price represents the weighted average sales price of multiple transactions on the reported date at prices that ranged between $2.9804 and $2.9806. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.
- This price represents the weighted average sales price of multiple transactions on the reported date at prices that ranged between $3.0506 and $3.0606. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.